Stiris Research Inc. Awarded Pivotal Pre-Hospital Cardiovascular Study

London, ON — March 17, 2022 —

Stiris Research (“Stiris”) a Clinical Trial Management company focused on the management of Phase I-IIIB trials, today announces it has been awarded a Phase III Pre-Hospital Cardiovascular study.

“We have an opportunity to collaborate globally with some great leaders.  There are a lot of moving parts in a pre-hospital study, and the thing I love hearing most is how the team, regardless of country, is so focused on providing the best care to patients and the sites. We’re tapping into each other’s experiences to keep the study moving efficiently and so we can provide the best service and support. This is a pivotal study for patients, and I couldn’t imagine a better collaboration to deliver it.” said Shantal Feltham, Stiris’ President & CEO.

Pre-hospital management (including rapid diagnosis and intervention) of an acute myocardial infarction (AMI) has been shown to reduce morbidity and mortality rates amongst patients. Trained paramedics providing early application of interventional treatments has shown considerable success in survival rates. Approximately 12 million lives are lost annually from the effects of cardiovascular disease (WHO) and 50% of AMI patients die prior to reaching hospital.


About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS/Neurology, Endocrinology and Rare Disease. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.